UCLA scientists use stem cells to study genetics of germ cell tumors
UCLA researchers have made new inroads into understanding germ cell tumors, a diverse and rare group of cancers that begin in germ cells — the cells that develop into sperm and eggs. The researchers developed a protocol to recreate germ cell tumor cells from stem cells and used the new model to study the genetics of the cancer.Their findings could point the way toward new drugs to treat germ cell tumors, which account for around 3 percent of all cases of childhood and adolescent cancer.The study, published in Stem Cell Research, was led by Amander Clark, a UCLA professor of molecular cell and developmental biology and a member of theEli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA.Germ cell tumors most often develop during embryonic development, in the testes and ovaries, but they can also occur in the spine, chest and brain when germ cells mistakenly migrate there.UCLA Broad Stem Cell Research Center/ElsevierEmbryonal carcinoma cells expressing the PRDM14 proteinThere are five subtypes of germ cell tumors: germinomas, embryonal carcinomas, yolk sac tumors, choriocarcinomas and teratomas. Each has its own unique properties, but most of them affect young children, adolescents and young adults.“What makes this cancer really hard to study is that we think the disease begins in the womb and then remains latent until after birth or during young adulthood,” Clark said. “That means we can’t easily isolate or study the ...
Qi Liu, Dakui Luo, Qingguo Li, Ji Zhu, Xinxiang Li
ConclusionsWhen compared to other radioresistant histologies, HCC has inferior local control and pain relief after SRS. Whether HCC may benefit from further dose escalation or combined treatment with new therapies is an area of future research.
Researchers examined whether a higher Gleason score impacts the efficacy of androgen deprivation therapy.
A recent study inJAMA Oncology compared survival for various multi-modality approaches for treating aggressive prostate cancer.
The long-term results from an analysis of two phase II studies confirmed the role of osimertinib in the treatment of T790M mutation –positive advanced non–small-cell lung cancer.
In patients with HER2-positive breast cancer treated with anthracyclines plus trastuzumab, can adding lisinopril or carvedilol reduce the risk of cardiotoxicity?
A comparison of chemotherapy regimens plus anti-HER2 therapy in the neoadjuvant setting tested whether the addition of anthracyclines is necessary for patients with HER2-positive breast cancer.
Having a baby temporarily increases the risk of breast cancer by about 80% compared to the risk in women who have never given birth, researchers behind a new study have concluded.Reuters Health Information
When it's unclear whether the potential benefit of breast cancer screening outweighs the possible harms, doctors should encourage women to make an informed decision based on their personal preferences, Canadian doctors recommend.Reuters Health Information
Grants for research that examines how health information technology adoption impacts minority health and health disparity populations in access to care, quality of care, patient engagement, and health outcomes. Geographic coverage: Nationwide -- National Cancer Institute, National Institute on Minority Health and Health Disparities, National Institutes of Health, Office of Behavioral and Social Sciences Research, U.S. Department of Health and Human Services
More News: Biology | Brain | Brain Cancers | Cancer | Cancer & Oncology | Cancer in Adolescents | Cancer in Young Adults | Carcinoma | Cardiology | Career Development | Chemotherapy | Child Development | Childhood Cancer | Children | Choriocarcinoma | Cytology | Embryonal Carcinoma | Genetics | Germ Cell Tumors | Girls | Grants | Heart | Heart Disease | Infertility | Molecular Biology | Neurology | Ovarian Cancer | Ovaries | Pathology | Pediatrics | Reproduction Medicine | Seminoma | Skin | Stem Cell Therapy | Stem Cells | Study | Teratoma | Testicular Cancer | Training | Universities & Medical Training | Yolk Sac Tumor